Brii Bio Allocates $100 Million to Bring Dual SARS-CoV-2 mAb Therapy to Market

Brii Biosciences of Beijing  committed an additional $100 million for global regulatory filings and commercialization of its SARS-CoV-2 combination therapy. BRII-196/BRII-198 is a neutralizing monoclonal antibody combination therapy. In a Phase III trial, interim results showed a statistically significant reduction of 78% in hospitalization/death among high risk, non-hospitalized COVID-19 patients. The results showed efficacy in all variants of the disease. The company will also expand manufacturing and establish partnerships to deliver the therapy globally. More details.... Stock Symbol: (HK: 2137) Share this with colleagues: // //